ProCE Banner Activity

Phase III PROUD-PV: Ropeginterferon α-2b Noninferior to Hydroxyurea in Polycythemia Vera

Slideset Download
Conference Coverage
Results from the phase III trial showed fewer treatment-related AEs, dose reductions, and secondary malignancies in patients receiving ropeginterferon α-2b compared with those receiving hydroxyurea.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen